- Home
- GOSS vs GRAF Comparison
GOSS vs GRAF Comparison
Compare GOSS & GRAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- GRAF
- Stock Information
- Founded
- GOSS 2015
- GRAF 2021
- Country
- GOSS United States
- GRAF United States
- Employees
- GOSS N/A
- GRAF N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- GRAF
- Sector
- GOSS Health Care
- GRAF
- Exchange
- GOSS Nasdaq
- GRAF NYSE
- Market Cap
- GOSS 262.5M
- GRAF 294.4M
- IPO Year
- GOSS 2019
- GRAF 2024
- Fundamental
- Price
- GOSS $1.40
- GRAF $10.45
- Analyst Decision
- GOSS Strong Buy
- GRAF
- Analyst Count
- GOSS 4
- GRAF 0
- Target Price
- GOSS $7.75
- GRAF N/A
- AVG Volume (30 Days)
- GOSS 1.3M
- GRAF 10.4K
- Earning Date
- GOSS 08-11-2025
- GRAF 01-01-0001
- Dividend Yield
- GOSS N/A
- GRAF N/A
- EPS Growth
- GOSS N/A
- GRAF N/A
- EPS
- GOSS N/A
- GRAF 0.32
- Revenue
- GOSS $124,590,000.00
- GRAF N/A
- Revenue This Year
- GOSS N/A
- GRAF N/A
- Revenue Next Year
- GOSS $91.14
- GRAF N/A
- P/E Ratio
- GOSS N/A
- GRAF $32.41
- Revenue Growth
- GOSS N/A
- GRAF N/A
- 52 Week Low
- GOSS $0.55
- GRAF $9.03
- 52 Week High
- GOSS $1.55
- GRAF $11.02
- Technical
- Relative Strength Index (RSI)
- GOSS 57.95
- GRAF N/A
- Support Level
- GOSS $1.22
- GRAF N/A
- Resistance Level
- GOSS $1.36
- GRAF N/A
- Average True Range (ATR)
- GOSS 0.08
- GRAF 0.00
- MACD
- GOSS -0.00
- GRAF 0.00
- Stochastic Oscillator
- GOSS 66.07
- GRAF 0.00
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About GRAF GRAF GLOBAL CORP
Graf Global Corp is a blank check company.